Dr. Vremeș Georgeta

Despre Dr. Vremeș Georgeta

Studii și experiență profesională

2019- Prezent Medic Primar – Oncologie Medicală Breast Institute Bucureşti
2018- Prezent Medic Primar – Oncologie Medicală Spitalul Medlife Titan Bucureşti
2012- 2018 Medic Primar – Oncologie Medicală Life Memorial Hospital Bucureşti
2008-2012 Medic Specialist – Oncologie Medicala Life Memorial Hospital Bucureşti
2007-2008 Medic Specialist – Oncologie Medicala Institutul Oncologic Bucuresti Bucureşti
2003-2007 Medic Rezident – Oncologie Medicala Institutul Oncologic Bucuresti Bucureşti
2002-2003 Medic Rezident – Medicina de Familie Spitalul Judeţean Brasov Brasov
2001 Absolventa a Facultaţii de Medicină Generală – Universitatea de Vest „ Vasile Goldis ” Arad
1994 Absolventa a Liceului Teoretic „Dinicu Golescu” Cimpulung

Cursuri postuniversitare

ESMO – 2-4 Apr 2004
Fundamentals in Medical Oncology

ESMO 5x5x5 Educational Program – 30 Sep – 2 Oct 2004
Head and Neck, Thoracic Tumors

ESMO 5x5x5 Educational Program – 23-25 Sep 2005
Gastrointestinals Tumors

ESMO 5x5x5 Educational Program – 19-21 Apr 2007
Course on Molecular Targeted Therapy in Oncology: hopes, facts and further promises

ESMO 5x5x5 Educational Program 10-12 Mai 2007
Palliative Care and Supportive Care in Medical Oncology Practice

Traning ICH-GCP Noiembrie 2020

Evaluare profesionala la standarde europene

EUROPEAN CERTIFICATION IN MEDICAL ONCOLOGY- 23 Sept 2007 Barcelona, Spania

EUROPEAN RECERTIFICATION APPROVAL IN MEDICAL ONCOLOGY- Nov 2012

Membru al asociaţiilor profesionale

Societatea Română de Oncologie Medicală din 2003

European Society of Medical Oncology (ESMO) din 2005

Balkan Union of Oncology (B.U.O.N.) din 2005

American Society of Clinical Oncology (ASCO) din 2006

Articole științifice

Chemotherapy for resectable non-small cell lung cancer. It’s time for a change in the current paradigm
M.Dediu, Aurelia Alexandru, D.Median, Georgeta Vremes
A Special edition of Journal of BUON 2005, Sept; 61- 88. ISSN 1107-0625.First Educational Course of BSO Volos, Greece, 16-17 Sep. 2005

Atelectasis as a good prognostic factor for advanced non-small cell lung cancer (NSCLC)
M. Dediu, Rodica Anghel, D. Median, Aurelia Alexandru, D. Nuţu, A.Ţârlea, Anca Silaghi, Georgeta Vremeş, C.Gal, Loredana Nedeluş
31st ESMO Congress, Istanbul, Turkey, 29Sep – 03Oct 2006

Experiență studii clinice

Poziţie	Aria terapeutică	Indicatie	Faza studiului
Sub-investigator	removab vs. paracenteza	Ascita maligna	II / III
Sub-investigator	Co-factor si 5 FU vs. LV si 5 FU	Cancer de colon metastatic	II B
Sub-investigator	Bevacizumab si chimioterapie	Cancer de colon metastatic	IIIB
Sub-investigator	Panitumumab+ FOLFIRI vs. FOLFIRI	Cancer de colon metastatic	III
Sub-investigator	Chimioterapie +/-Bevacizumab	Cancer de san metastatic	III
Sub-investigator	Topotecan vs. karenitecin	Cancer ovarian avansat	III
Sub-investigator	Chimioterapie + G-CSF	Cancer de san metastatic	III
Sub-investigator	Tapendadol vs. Morfina	Durere	III
Sub-investigator	Chimioterapie+/- Sunitinib	Cancer de san	III
Principal- Investigator	Chimioterapie+/- Rilotumumab	Cancer gastric metastatic	III